Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles ImmuCell Corporation’s (Nasdaq: ICCC) SEC filings, giving investors structured access to the company’s regulatory disclosures as an animal health business focused on dairy and beef cattle. ImmuCell’s filings include current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, along with other exhibits and agreements.
Through these documents, readers can review ImmuCell’s reported product sales for its First Defense® line, commentary on trends in domestic and international sales, and management’s discussion of gross margins, net income or loss, and backlog dynamics. Filings also describe the development status of Re-Tain®, including the New Animal Drug Application process, investigational product use, and the company’s decision to pause further direct investment after receiving an FDA Incomplete Letter related to a contract manufacturer.
ImmuCell’s SEC reports provide detail on financing arrangements, such as loan agreements and lines of credit with Maine Community Bank, refinancing transactions, and related security interests in company assets. They also disclose corporate governance and leadership changes, including CEO succession, board expansion, and executive employment agreements, as well as other material definitive agreements.
On Stock Titan, these filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain lengthy 10-K and 10-Q reports, highlight key risk factors and business updates, and clarify the implications of Form 8-K events. Users can also quickly identify information about executive and board changes, financing obligations and other material developments affecting ImmuCell’s cattle health-focused operations.
ImmuCell Corporation is asking stockholders to vote at its June 11, 2026 virtual annual meeting. Holders of 9,046,799 common shares as of April 13, 2026 can elect seven directors, cast an advisory “say-on-pay” vote, and ratify Wipfli LLP as auditor.
Stockholders are also asked to approve the 2025 Stock Option and Incentive Plan, which authorizes up to 650,000 shares and has 403,777 options already granted, largely contingent on approval, and to amend the charter to add Delaware-permitted officer exculpation.
The proxy highlights a leadership transition to new CEO P. Olivier te Boekhorst, a strategic focus on the First Defense® product line, efforts to partner Re-Tain®, creation of a Strategy & Technology Committee, and updated compensation and equity policies for executives and directors.
ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options. These options cover 17,899 shares of common stock at an exercise price of $7.60 per share and expire on April 15, 2036.
The options vest over three years: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares on April 15, 2029. This filing records DiMarco’s derivative equity position; it does not show any recent buy or sell transaction.
ImmuCell Corp (ICCC) director Gilles Guillemette filed an initial Form 3 reporting stock option holdings. The filing shows non-qualified stock options to acquire 17,899 shares of common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest in three equal annual installments: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares become exercisable on April 15, 2029. All reported holdings are owned directly.
ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options give her the right to buy an equal number of ImmuCell common shares at an exercise price of $7.60 per share and represent a compensation award rather than an open-market purchase.
The options vest over three years, with 5,966 options becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 options vesting on April 15, 2029. All of the options expire on April 15, 2036 if they are not exercised.
ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.
ImmuCell director Gloria F. Basse received a grant of 11,933 non-qualified stock options to buy ImmuCell common stock. The options have an exercise price of $7.60 per share and expire on April 15, 2036.
All 11,933 options were awarded as compensation and are held directly. According to the vesting schedule, 3,977 options become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 options become exercisable on April 15, 2029.
ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation. He was awarded options to buy 11,933 shares of ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over three years: 3,977 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares on April 15, 2029. After this grant, Wainman holds 11,933 stock options directly, indicating a compensation-related equity award rather than an open-market purchase or sale.
ImmuCell Corporation is soliciting proxies for its remote Annual Meeting of Stockholders to be held June 11, 2026, with a record date of April 13, 2026. The meeting will consider: election of seven directors; a non-binding advisory vote on executive compensation; approval of the 2025 Stock Option and Incentive Plan; an amendment to the Certificate of Incorporation to add officer exculpation under Delaware law; and ratification of Wipfli LLP as independent auditors.
The 2025 Plan would authorize up to 650,000 shares. The proxy discloses director pay changes (non-employee director annual fee increased to $40,000 effective January 1, 2026), named executive officer compensation details (e.g., CEO total 2025 compensation $675,934), outstanding option and plan balances (total options outstanding 801,760; weighted-average exercise price $6.20), and governance items including committee structures and related-party disclosure.
ImmuCell Corp. director Bryan K. Gathagan received a grant of non-qualified stock options for 10,000 shares of common stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this grant, he holds 10,000 options directly.
ImmuCell Corp. director Paul R. Wainman received a grant of stock options as part of his compensation. On April 16, 2025, he was awarded non-qualified options to acquire 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share.
The options become exercisable on April 16, 2028 and expire on April 16, 2030. Following this grant, Wainman holds 10,000 stock options directly, and this filing does not show any sales or open-market purchases of common stock.